The DESTINY-Breast04 trial spotlighted the superior efficacy of HER2-targeted antibody-drug conjugates (ADCs) compared to standard chemotherapy options in patients with HER2-low advanced breast cancer (6). Here, ERBB2 is linked to breast cancer.